Entrada Therapeutics Inc banner

Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 13.2 USD 3.94%
Market Cap: $504.5m

Wall Street
Price Targets

TRDA Price Targets Summary
Entrada Therapeutics Inc

Wall Street analysts forecast TRDA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRDA is 18.87 USD with a low forecast of 13.13 USD and a high forecast of 22.05 USD.

Lowest
Price Target
13.13 USD
1% Downside
Average
Price Target
18.87 USD
43% Upside
Highest
Price Target
22.05 USD
67% Upside
Entrada Therapeutics Inc Competitors:
Price Targets
SANA
Sana Biotechnology Inc
159% Upside
SUPN
Supernus Pharmaceuticals Inc
19% Upside
SSRM
SSR Mining Inc
5% Upside
VINP
Vinci Partners Investments Ltd
28% Upside
PRQR
ProQR Therapeutics NV
410% Upside
STG
Strip Tinning Holdings PLC
143% Upside

Revenue
Forecast

N/A
Past Growth
-25% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
-25% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Entrada Therapeutics Inc's revenue for the next 4 years is -25%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TRDA's stock price target?
Price Target
18.87 USD

According to Wall Street analysts, the average 1-year price target for TRDA is 18.87 USD with a low forecast of 13.13 USD and a high forecast of 22.05 USD.

What is Entrada Therapeutics Inc's Revenue forecast?
Projected CAGR
-25%

The compound annual growth rate of Entrada Therapeutics Inc's revenue for the next 4 years is -25%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett